http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110151791-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 |
| filingDate | 2019-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110151791-B |
| titleOfInvention | Application of endothelial progenitor cells in the treatment of coronary microembolism in rats |
| abstract | The present invention relates to the treatment of coronary microembolization. Coronary microembolization (CME) is a very common and important clinical event in acute coronary syndrome and coronary intervention. The present invention found that low-dose EPC transplantation can increase endothelial cell growth factor VEGF and capillary formation, and inhibit the formation of blood vessels. Fibroblast growth factor bFGF can alleviate myocardial tissue lesions and myocardial collagen fiber hyperplasia caused by CME, providing a new strategy for the treatment of CME. |
| priorityDate | 2019-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 174.